sleep thatgoes deeper
dosed at bedtime to sit with your natural overnight GH pulse. sleep is the change people report first, and it is not a measurement.
ODTIGF-1class-level evidence
sermorelin
dissolves under the tongue at bedtime, timed to your overnight growth hormone pulse.
- what you get
- sermorelin, orally dissolving tablet
- how you take it
- nightly at bedtime, on an empty stomach
- dosing
- set to your baseline IGF-1
- dispensed by
- a licensed US compounding pharmacy
- reviewed at
- week 12, with a stopping rule
$149/mosee if you qualify
a physician decides what is right for you. if this is not a fit, your first panel is on us.
compounded by a licensed US pharmacy. sermorelin was approved as Geref and withdrawn from the US market in 2008 for commercial reasons, not safety findings.
4 to 12 weeks
the window in which IGF-1 responds, when it responds
growth hormone secretagogue literature
what this does for you
IGF-1 thatactually moves
the endpoint everything is judged on. we look for a rise into the upper half of your age-adjusted range by week twelve.
recovery youcan measure
class data on GHRH analogs reports more lean mass and less visceral fat across three to six months of use.
no modern phase III trial exists for the indications people seek sermorelin for, because the molecule is off-patent and no sponsor has funded one. its pharmacology, though, is well characterized: it stimulates endogenous GH release, and IGF-1 rises measurably when it works. so we treat IGF-1 as the endpoint and set a stopping rule at week twelve, rather than inferring a result we cannot see.
why we measure it, and what we are reading
a prescription without a follow-up draw is a guess with a receipt. every marker below has a direction we expect and a date we check it, and all of it is read against your own baseline rather than a population range.
IGF-1quarterly
the endpoint. we look for a rise into the upper half of the age-adjusted range. no movement by week twelve means it is not working in you.
morning cortisolquarterly
read alongside your sleep. slow recovery is often an HPA-axis or sleep problem rather than a GH one, and treating the wrong axis costs months.
hs-CRPquarterly
low-grade systemic inflammation. when this is raised it usually explains more of how you feel than IGF-1 does.
fasting glucosemonthly
GH is counter-regulatory to insulin, so this is a safety marker here. it sits on the monthly panel rather than the quarterly one for that reason.
CBCquarterly
standard hematologic safety panel.
what happens, and when
before you start
baseline IGF-1 against the age-adjusted range. every later decision is made against this number.
IGF-1, cortisol, hs-CRP, glucoseweeks 1 to 4
nightly at bedtime on an empty stomach, to align with your natural overnight pulse. sleep is often the first thing people notice, and sleep is not a measurement.
fasting glucoseweeks 4 to 12
the window in which IGF-1 responds, when it is going to.
IGF-1, glucoseweek 12
the stopping rule. IGF-1 has risen or it has not, and if it has not we stop rather than extend.
the full panel against your baselinethis is a fit if
- your baseline IGF-1 sits in the lower half of the age-adjusted range
- you are training hard, recovering slowly, or sleeping poorly
- you would rather have a measurable endpoint than a subjective one
- a defined stopping rule at week twelve suits you
this is not for you if
- you are pregnant or breastfeeding
- you have an active or recently treated malignancy
- you have diabetes or uncontrolled fasting hyperglycemia
- you have active pituitary disease or untreated proliferative retinopathy
the detail
sermorelin is GRF(1-29), the active fragment of the growth hormone-releasing hormone your hypothalamus already produces. it stimulates your own pituitary rather than replacing the hormone. secretion stays pulsatile and subject to normal feedback, which is the meaningful difference from injected growth hormone. GH is released in pulses and cleared within minutes, so a random blood level tells you nothing. IGF-1 is its stable downstream product and the standard way to read the axis.
nothing here is offered before it is measured.
start my labsall treatments
- review of growth hormone secretagogues in body composition management, 2020. reports higher IGF-1 and improved lean mass across three to six months, and characterizes the clinical outcome evidence as still developing.
- Geref (sermorelin acetate) US market withdrawal, 2008, for commercial reasons.
compounded medications are not FDA-approved and are prescribed at the discretion of a licensed physician. this page is information, not medical advice. prova does not replace your primary care provider.
